{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:18:19Z","timestamp":1790201899801,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Leprosy remains a significant public health concern despite major strides in treatment and control efforts. The Global Leprosy Strategy 2021\u20132030 and the National Strategic Plan for Leprosy 2023\u20132027 majorly focus on facilitating action to reach the goal of zero leprosy. Exploration of new treatment regimens is emphasized as one of the verticals of the multipronged approach for reaching the aforementioned goals. This becomes particularly pertinent in the wake of growing evidence for resistance to the drugs currently being used in the management of leprosy. Repurposed molecules present a very good approach in this direction. The present review aims to explore the potential of bedaquiline, a drug used for multidrug\u2010resistant tuberculosis, as a potential addition to the therapeutic armamentarium of leprosy. Through this narrative review, the authors attempt to look into the available proof of concept, clinical evidence, potential risks, and possible ways forward with bedaquiline in leprosy.<\/jats:p>","DOI":"10.1111\/ijd.17485","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T13:38:23Z","timestamp":1726061903000},"page":"266-271","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring the therapeutic and prophylactic potential of bedaquiline in leprosy"],"prefix":"10.1111","volume":"64","author":[{"given":"Himanshi","family":"Khera","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, Department of Pharmacology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Narang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9495-7502","authenticated-orcid":false,"given":"Apoorva","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Department of Pharmacology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Kumar","sequence":"additional","affiliation":[{"name":"ICMR\u2010National JALMA Institute of Leprosy &amp; Other Mycobacterial Diseases  Agra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2925-5608","authenticated-orcid":false,"given":"Seema","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Department of Immunopathology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Khan","sequence":"additional","affiliation":[{"name":"ICMR\u2010National JALMA Institute of Leprosy &amp; Other Mycobacterial Diseases  Agra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Suri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dogra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7053-003X","authenticated-orcid":false,"given":"Nusrat","family":"Shafiq","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Department of Pharmacology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8652062"},{"key":"e_1_2_5_3_1","unstructured":"https:\/\/ilepfederation.org\/global\u2010leprosy\u2010%E2%80%8Ehansens\u2010disease%E2%80%8E\u2010strategy\u20102021\u20102030\u2010towards\u2010zero\u2010leprosy\/"},{"key":"e_1_2_5_4_1","unstructured":"https:\/\/dghs.gov.in\/WriteReadData\/userfiles\/file\/Leprosy%20New\/NSP%20%20Roadmap%20for%20Leprosy%202023\u20102027.pdf"},{"key":"e_1_2_5_5_1","unstructured":"https:\/\/www.who.int\/publications\/journals\/weekly\u2010epidemiological\u2010record"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.47276\/lr.83.3.269"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/003335490812300212"},{"key":"e_1_2_5_8_1","unstructured":"World Health Organization.Chemotherapy of leprosy for control programmes: report of a WHO study group (meeting held in Geneva from 12 to 16 October 1981).https:\/\/www.ijl.org.in\/published\u2010articles\/14092021172340\/7_N_Saraswat_et_al_(225\u2010232)(1).pdf"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.2.338-381.2006"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07279"},{"key":"e_1_2_5_11_1","unstructured":"(Guidelines for the diagnosis treatment and prevention of leprosy) 6 October 2018.https:\/\/www.who.int\/publications\/i\/item\/9789290226383"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0256"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012443"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2023.10.006"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.022"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.06.008"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1706930"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70412-1"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.31891"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.161"},{"key":"e_1_2_5_21_1","first-page":"1","article-title":"MIP vaccine in leprosy: a scoping review and future horizons","volume":"3","author":"Narang T","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1558-1560.2006"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.02.017"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2019.10.002"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.23.0185"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00272-17"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2019.05.008"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2014.01.022"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8040261"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01817-w"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582325"},{"key":"e_1_2_5_32_1","unstructured":"https:\/\/tbcindia.gov.in\/showfile.php?lid=3246"},{"key":"e_1_2_5_33_1","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03384641?cond=multibacilliary%20leprosy&intr=Bedaquiline%20100%20MG&rank=1"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00722-09"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011379"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08290-0"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T04:40:14Z","timestamp":1737780014000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/ijd.17485"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17485","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"2024-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}